These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 2530063

  • 1. Immune complex modulation by plasma proteins. With special reference to the complement system and autoimmune diseases.
    Baatrup G.
    Dan Med Bull; 1989 Oct; 36(5):443-63. PubMed ID: 2530063
    [Abstract] [Full Text] [Related]

  • 2. Control of immune complexes by the classical pathway.
    Whaley K, Ahmed AE.
    Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
    [Abstract] [Full Text] [Related]

  • 3. Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.
    Baatrup G, Petersen I, Jensenius JC, Svehag SE.
    Clin Exp Immunol; 1983 Nov; 54(2):439-47. PubMed ID: 6652967
    [Abstract] [Full Text] [Related]

  • 4. Activation of rat complement by soluble and insoluble rat IgA immune complexes.
    Rits M, Hiemstra PS, Bazin H, Van Es LA, Vaerman JP, Daha MR.
    Eur J Immunol; 1988 Dec; 18(12):1873-80. PubMed ID: 3220102
    [Abstract] [Full Text] [Related]

  • 5. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ.
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [Abstract] [Full Text] [Related]

  • 6. Complement mediated solubilization: role of the complement in the clearance of circulating immune-complexes.
    Sánchez-Cuenca JM.
    Allergol Immunopathol (Madr); 1994 Sep; 22(5):197-203. PubMed ID: 7840020
    [Abstract] [Full Text] [Related]

  • 7. Prevention of immune precipitation by purified components of the alternative pathway.
    Naama JK, Holme E, Hamilton E, Whaley K.
    Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
    [Abstract] [Full Text] [Related]

  • 8. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
    Corvetta A, Spaeth PJ, Ghirelli PA, Orecchioni F, Buetler R, Montroni M, Nydegger UE.
    Diagn Immunol; 1983 Apr; 1(4):315-23. PubMed ID: 6333960
    [Abstract] [Full Text] [Related]

  • 9. The complement system in systemic autoimmune disease.
    Chen M, Daha MR, Kallenberg CG.
    J Autoimmun; 2010 May; 34(3):J276-86. PubMed ID: 20005073
    [Abstract] [Full Text] [Related]

  • 10. Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.
    Schifferli JA, Steiger G, Hauptmann G, Spaeth PJ, Sjöholm AG.
    J Clin Invest; 1985 Dec; 76(6):2127-33. PubMed ID: 2934406
    [Abstract] [Full Text] [Related]

  • 11. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G, Jonsson H, Sjöholm A, Sturfelt G, Svehag SE.
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [Abstract] [Full Text] [Related]

  • 12. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM, Gleich GJ.
    J Immunol; 1988 Mar 01; 140(5):1605-10. PubMed ID: 3346544
    [Abstract] [Full Text] [Related]

  • 13. Complement deficiencies and systemic lupus erythematosus.
    Truedsson L, Bengtsson AA, Sturfelt G.
    Autoimmunity; 2007 Dec 01; 40(8):560-6. PubMed ID: 18075790
    [Abstract] [Full Text] [Related]

  • 14. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
    Nielsen EW, Waage C, Fure H, Brekke OL, Sfyroera G, Lambris JD, Mollnes TE.
    Mol Immunol; 2007 Mar 01; 44(8):1819-26. PubMed ID: 17101176
    [Abstract] [Full Text] [Related]

  • 15. Physiology and pathophysiology of complement: progress and trends.
    Morgan BP.
    Crit Rev Clin Lab Sci; 1995 Mar 01; 32(3):265-98. PubMed ID: 7495498
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F, Kijlstra A.
    Immunology; 1985 Mar 01; 54(3):449-56. PubMed ID: 3844370
    [Abstract] [Full Text] [Related]

  • 17. Complement, antigen-antibody complexes and immune complex disease.
    Naama JK, Niven IP, Zoma A, Mitchell WS, Whaley K.
    J Clin Lab Immunol; 1985 Jun 01; 17(2):59-67. PubMed ID: 2931531
    [No Abstract] [Full Text] [Related]

  • 18. [Elimination of immune complexes: role of complement].
    Schifferli JA.
    Schweiz Med Wochenschr; 1985 Oct 12; 115(41):1422-4. PubMed ID: 2933806
    [Abstract] [Full Text] [Related]

  • 19. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
    Arroyave CM, Wilson MR, Tan EM.
    J Immunol; 1976 Mar 12; 116(3):821-6. PubMed ID: 815434
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of complement-dependent phagocytosis by monocytes following pre-incubation with immune complexes and interaction with plasma.
    Pinching AJ.
    Clin Exp Immunol; 1983 Jan 12; 51(1):83-90. PubMed ID: 6831773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.